Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01230853 · ClinicalTrials.gov registry record · Phase 1
A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study
A Phase 1 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT01230853 is a Phase 1 study that has completed, run by Eisai. The registered enrollment target is 80 participants.
The verdict
NCT01230853, a Phase 1 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
The purpose of this study will be to evaluate the safety and tolerability of lecanemab at sequentially ascending doses in subjects with mild to moderate Alzheimer's disease (AD).
Interventions
- DRUG Active Comparator: A
- DRUG Placebo Comparator B
- DRUG Active Comparator B
- DRUG Placebo Comparator A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2010-08 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01230853
The ClinicalTrials.gov registry entry for NCT01230853 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Active Comparator: A is the first listed.
NCT01230853 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01230853 about?
NCT01230853 is a clinical study titled "A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study". The purpose of this study will be to evaluate the safety and tolerability of lecanemab at sequentially ascending doses in subjects with mild to moderate Alzheimer's disease (AD).
What is the current status of trial NCT01230853?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2010-08. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01230853?
The interventions under investigation include: Active Comparator: A (DRUG), Placebo Comparator B (DRUG), Active Comparator B (DRUG), Placebo Comparator A (DRUG).
Who is sponsoring clinical trial NCT01230853?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.